Advertisement
CELZ vs IOVA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELZ is a Hold and IOVA is a Hold.
CELZ in downward trend: 10-day moving average moved below 50-day moving average on September 17, 2026
The 10-day moving average for CELZ crossed bearishly below the 50-day moving average on September 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CELZ as a result. In 87 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CELZ turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 35 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
CELZ moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for CELZ entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CELZ's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where CELZ advanced for three days, in 200 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
CELZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.650) is normal, around the industry mean (2.835). P/E Ratio (-0.361) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (833.333) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CELZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IOVA in -2.40% downward trend, falling for three consecutive days on October 14, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where IOVA declined for three days, in 282 of 323 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IOVA moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 26 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IOVA as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for IOVA turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
IOVA broke above its upper Bollinger Band on September 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a +13.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where IOVA advanced for three days, in 196 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 135 of 155 cases where IOVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.534) is normal, around the industry mean (2.835). P/E Ratio (-19.739) is within average values for comparable stocks, (-0.607). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.264) among similar stocks. P/S Ratio (12.484) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 31 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. IOVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
CELZ | IOVA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 16 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 97 | |
PRICE GROWTH RATING 1..100 | 86 | 34 | |
P/E GROWTH RATING 1..100 | 20 | 31 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IOVA's Valuation (16) in the Biotechnology industry is significantly better than the same rating for CELZ (85) in the null industry. This means that IOVA’s stock grew significantly faster than CELZ’s over the last 12 months.
IOVA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CELZ (100) in the null industry. This means that IOVA’s stock grew similarly to CELZ’s over the last 12 months.
IOVA's SMR Rating (97) in the Biotechnology industry is in the same range as CELZ (98) in the null industry. This means that IOVA’s stock grew similarly to CELZ’s over the last 12 months.
IOVA's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for CELZ (86) in the null industry. This means that IOVA’s stock grew somewhat faster than CELZ’s over the last 12 months.
CELZ's P/E Growth Rating (20) in the null industry is in the same range as IOVA (31) in the Biotechnology industry. This means that CELZ’s stock grew similarly to IOVA’s over the last 12 months.
| CELZ | IOVA | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 90% | 4 days ago 84% |
| Stochastic ODDS (%) | 4 days ago 77% | 4 days ago 87% |
| Momentum ODDS (%) | 4 days ago 88% | 4 days ago 86% |
| MACD ODDS (%) | 4 days ago 88% | 4 days ago 87% |
| TrendWeek ODDS (%) | 4 days ago 87% | 4 days ago 88% |
| TrendMonth ODDS (%) | 4 days ago 87% | 4 days ago 85% |
| Advances ODDS (%) | 18 days ago 85% | 11 days ago 79% |
| Declines ODDS (%) | 6 days ago 85% | 6 days ago 87% |
| BollingerBands ODDS (%) | 6 days ago 90% | 4 days ago 83% |
| Aroon ODDS (%) | 4 days ago 85% | 4 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CELZ’s FA Score shows that 1 FA rating(s) are green while IOVA’s FA Score has 2 green FA rating(s).
- CELZ’s FA Score: 1 green, 4 red.
- IOVA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CELZ’s TA Score shows that 4 TA indicator(s) are bullish while IOVA’s TA Score has 2 bullish TA indicator(s).
- CELZ’s TA Score: 4 bullish, 6 bearish.
- IOVA’s TA Score: 2 bullish, 6 bearish.
Price Growth
CELZ (@Biotechnology) experienced а -11.63% price change this week, while IOVA (@Biotechnology) price change was -6.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -7.77%. For the same industry, the average monthly price growth was -18.56%, and the average quarterly price growth was -19.45%.
Reported Earning Dates
CELZ is expected to report earnings on Dec 02, 2026.
IOVA is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Biotechnology (-7.77% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
CELZ and
Correlation & Price change
A.I.dvisor tells us that CELZ and WVE have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELZ and WVE's prices will move in lockstep.
| Ticker / NAME | Correlation To CELZ | 1D Price Change % | ||
|---|---|---|---|---|
| CELZ | 100% | -9.39% | ||
| WVE - CELZ | 30% Poorly correlated | -1.88% | ||
| TRDA - CELZ | 29% Poorly correlated | -8.58% | ||
| GNPX - CELZ | 28% Poorly correlated | -7.86% | ||
| IOVA - CELZ | 26% Poorly correlated | -7.47% | ||
| ACET - CELZ | 26% Poorly correlated | -11.09% | ||
More | ||||
IOVA and
Correlation & Price change
A.I.dvisor indicates that over the last year, IOVA has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IOVA jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To IOVA | 1D Price Change % | ||
|---|---|---|---|---|
| IOVA | 100% | -7.47% | ||
| VCYT - IOVA | 43% Loosely correlated | -2.86% | ||
| VIR - IOVA | 39% Loosely correlated | -4.87% | ||
| NKTX - IOVA | 38% Loosely correlated | -6.74% | ||
| PLX - IOVA | 37% Loosely correlated | -2.96% | ||
| RXRX - IOVA | 36% Loosely correlated | -16.71% | ||
More | ||||